BioStock: PHI aims for US listing

July 11, 2024

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

fill or kill podcast

PHI som gäst i Fill or Kill podcast: Avsnitt 366

Lyssna på Fill or Kill intervjun med PHI vd Peter Egelberg.

Generic Business Image

BioStock: PHIs CEO eyes new business opportunities

BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Two images showing cell culturing of today and tomorrow

Aktiespararna: PHIs teknik är nu redo att förvandla regenerativ medicin till framtidens sjukvård

PHI går i spetsen för nästa generation av cell-analys instrumentering, och gör nu en företrädesemission för att kunna fortsätta expandera inom klinisk tillämpning. Läs hela intervjun på Aktiespararna.

January 7, 2020

CEO interview in BioStock

In the article published today by BioStock, the company’s CEO Peter Egelberg comments on the developments during the past autumn.

1…5 678